NCG-B2m-KO Mouse

NCG-B2m-KO is a triple-immunodeficient NCG mouse with a B2m gene knockout. B2M (also known as Ly-m11, beta2m, beta2-m, β2-microglobulin) is a component of the MHC complex essential for MHC I expression. NCG-B2m-KO mice express low levels of MHC I on cell membranes and are resistant to graft versus host disease (GvHD).OriginThe NCG mouse strain was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to CRL in 2016. Nanjing Galaxy Biopharma became Gempharmatech in 2019, while retaining oversight of the original NCG colony. GPT later modified the original NCG strain by knocking out the B2M gene creating the NCG-B2m-KO. The strain was transferred to Charles River in 2022.